OBJECTIVE: We sought to evaluate whether 17 alpha-hydroxyprogesterone caproate (17-OHP) reduces preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) <30 mm. STUDY DESIGN: In this multicenter randomized controlled trial, nulliparous women with a singleton gestation between 16 and 22 3/7 weeks with an endovaginal CL <30 mm (<10th percentile in this population) were randomized to weekly intramuscular 17-OHP (250 mg) or placebo through 36 weeks. The primary outcome was PTB <37 weeks. RESULTS: The frequency of PTB did not differ between the 17-OHP (n = 327) and placebo (n = 330) groups (25.1% vs 24.2%; relative risk, 1.03; 95% confidence interval, 0.79-1.35). There also was no difference in the composite adverse neonatal outcome (7.0% vs 9.1%; relative risk, 0.77; 95% confidence interval, 0.46-1.30). CONCLUSION: Weekly 17-OHP does not reduce the frequency of PTB in nulliparous women with a midtrimester CL <30 mm.
RCT Entities:
OBJECTIVE: We sought to evaluate whether 17 alpha-hydroxyprogesterone caproate (17-OHP) reduces preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) <30 mm. STUDY DESIGN: In this multicenter randomized controlled trial, nulliparous women with a singleton gestation between 16 and 22 3/7 weeks with an endovaginal CL <30 mm (<10th percentile in this population) were randomized to weekly intramuscular 17-OHP (250 mg) or placebo through 36 weeks. The primary outcome was PTB <37 weeks. RESULTS: The frequency of PTB did not differ between the 17-OHP (n = 327) and placebo (n = 330) groups (25.1% vs 24.2%; relative risk, 1.03; 95% confidence interval, 0.79-1.35). There also was no difference in the composite adverse neonatal outcome (7.0% vs 9.1%; relative risk, 0.77; 95% confidence interval, 0.46-1.30). CONCLUSION: Weekly 17-OHP does not reduce the frequency of PTB in nulliparous women with a midtrimester CL <30 mm.
Authors: Roberto Romero; Kypros Nicolaides; Agustin Conde-Agudelo; Ann Tabor; John M O'Brien; Elcin Cetingoz; Eduardo Da Fonseca; George W Creasy; Katharina Klein; Line Rode; Priya Soma-Pillay; Shalini Fusey; Cetin Cam; Zarko Alfirevic; Sonia S Hassan Journal: Am J Obstet Gynecol Date: 2011-12-11 Impact factor: 8.661
Authors: J C Carey; M A Klebanoff; J C Hauth; S L Hillier; E A Thom; J M Ernest; R P Heine; R P Nugent; M L Fischer; K J Leveno; R Wapner; M Varner Journal: N Engl J Med Date: 2000-02-24 Impact factor: 91.245
Authors: R L Goldenberg; J D Iams; B M Mercer; P J Meis; A H Moawad; R L Copper; A Das; E Thom; F Johnson; D McNellis; M Miodovnik; J P Van Dorsten; S N Caritis; G R Thurnau; S F Bottoms Journal: Am J Public Health Date: 1998-02 Impact factor: 9.308
Authors: J D Iams; R L Goldenberg; P J Meis; B M Mercer; A Moawad; A Das; E Thom; D McNellis; R L Copper; F Johnson; J M Roberts Journal: N Engl J Med Date: 1996-02-29 Impact factor: 91.245
Authors: Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Kristin M Myers; Helen Feltovich; Edoardo Mazza; Joy Vink; Michael Bajka; Ronald J Wapner; Timothy J Hall; Michael House Journal: J Biomech Date: 2015-03-11 Impact factor: 2.712
Authors: Flor M Munoz; Leonard E Weisman; Jennifer S Read; George Siberry; Karen Kotloff; Jennifer Friedman; Rosemary D Higgins; Heather Hill; Harry Seifert; Mirjana Nesin Journal: Clin Infect Dis Date: 2014-12-15 Impact factor: 9.079
Authors: Steve N Caritis; Raman Venkataramanan; Elizabeth Thom; Margaret Harper; Mark A Klebanoff; Yoram Sorokin; John M Thorp; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; William A Grobman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan Ramin Journal: Am J Obstet Gynecol Date: 2013-10-07 Impact factor: 8.661